Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $5.6 million.

  • Iradimed's Income from Continuing Operations rose 1043.99% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.5 million, marking a year-over-year increase of 1907.69%. This contributed to the annual value of $18.5 million for FY2024, which is 1753.58% up from last year.
  • Latest data reveals that Iradimed reported Income from Continuing Operations of $5.6 million as of Q3 2025, which was up 1043.99% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Income from Continuing Operations registered a high of $5.8 million during Q2 2025, and its lowest value of $1.4 million during Q1 2021.
  • For the 5-year period, Iradimed's Income from Continuing Operations averaged around $3.8 million, with its median value being $3.9 million (2021).
  • Data for Iradimed's Income from Continuing Operations shows a peak YoY increase of 27919.82% (in 2021) and a maximum YoY decrease of 2161.2% (in 2021) over the last 5 years.
  • Over the past 5 years, Iradimed's Income from Continuing Operations (Quarter) stood at $3.9 million in 2021, then fell by 5.63% to $3.7 million in 2022, then fell by 15.13% to $3.1 million in 2023, then soared by 42.7% to $4.4 million in 2024, then rose by 25.34% to $5.6 million in 2025.
  • Its Income from Continuing Operations stands at $5.6 million for Q3 2025, versus $5.8 million for Q2 2025 and $4.7 million for Q1 2025.